Empasug-LG 25mg
MRP: 2
Packaging: 10X10
Pack Type: tablet
Composition:
Empagliflozin 25 mg + Linagliptin 5 mg IR
Indication:
Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. This combination of SGLT2 inhibitor (Empagliflozin) and DPP-4 inhibitor (Linagliptin) provides dual glucose-lowering effects. Not for type 1 diabetes or diabetic ketoacidosis.
Description:
Empagliflozin 25mg + Linagliptin 5mg IR is a potent fixed-dose combination tablet used for managing type 2 diabetes mellitus. This combination harnesses the benefits of two distinct antidiabetic agents:
Empagliflozin (25mg): A Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting its elimination through urine.
Linagliptin (5mg): A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that improves blood sugar control by enhancing insulin secretion and lowering glucagon levels in a glucose-dependent manner.
The higher 25mg dose of Empagliflozin is prescribed for patients who need intensified glycemic control beyond the 10mg dose. This combination offers effective blood sugar management with additional cardiovascular and renal protective effects, making it ideal for patients with multiple comorbidities. The immediate-release formulation ensures rapid onset of action for better glucose regulation.
Tags:
- Dual mechanism provides robust blood sugar control
- Supports weight loss or maintains weight neutrality
- Provides cardiovascular and renal protection
- Convenient once-daily dosing enhances compliance
- Lowers risk of hypoglycemia compared to some other therapies
Usage Information
Dosage
Take one tablet once daily, preferably in the morning. Can be taken with or without food. Dosage adjustments should be made by your healthcare provider. Maintain adequate hydration during therapy.
Side Effects
Common side effects: Increased urination Genital yeast infections Upper respiratory infections Thirst and dehydration Mild gastrointestinal upset Serious but rare side effects: Diabetic ketoacidosis Acute kidney injury Severe allergic reactions Hypotension (low blood pressure) Rare soft tissue infections (Fournier’s gangrene)
Contraindications
Type 1 diabetes mellitus Diabetic ketoacidosis Severe renal impairment (eGFR < 30 mL/min/1.73m²) Hypersensitivity to Empagliflozin, Linagliptin, or excipients History of pancreatitis (use with caution) Volume depletion or dehydration
Availability
Empagliflozin 25mg Linagliptin 5mg tablet SGLT2 and DPP-4 inhibitor combination Type 2 diabetes oral medication Empagliflozin Linagliptin benefits High dose Empagliflozin combination Blood sugar control diabetes treatment Empagliflozin Linagliptin side effects